A Novel Human Recombinant Lactoferrin Inhibits Lung Adenocarcinoma Cell Growth and Migration with No Cytotoxic Effect on Normal Human Epithelial Cells

Overview

Journal Arch Immunol Ther Exp (Warsz)

Publisher Sciendo

Specialty Allergy & Immunology

Date 2021 Nov 8

PMID 34748082

Citations 6

Authors

Paulina Olszewska

Barbara Pazdrak

Marian L Kruzel

Affiliations

Soon will be listed here.

Abstract

Lung cancer remains the leading cause of cancer death worldwide. Despite the recent advances in cancer treatment, only a subset of patients responds to targeted and immune therapies, and many patients developing resistance after an initial response. Lactoferrin (Lf) is a natural glycoprotein with immunomodulatory and anticancer activities. We produced a novel recombinant human Lf (rhLf) that exhibits glycosylation profile compatible with the natural hLf for potential parenteral therapeutic applications. The aim of this study was to evaluate the anticancer effects of this novel rhLf in human lung adenocarcinoma cells and its mechanisms of action. The results showed a concentration-dependent inhibition of A549 cancer cell growth in response to rhLf. Treatment with 1 mg/ml of rhLf for 24 h and 72 h resulted in a significant inhibition of cancer cell growth by 32% and 25%, respectively. Moreover, rhLf increased fourfold the percentage of early and late apoptotic cells compared to the control. This effect was accompanied by increased levels of caspase-3 activity and cell cycle arrest at the S phase in rhLf-treated cancer cells. Furthermore, rhLf significantly attenuated A549 cell migration. Importantly, treatment of normal human bronchial epithelial (NHBE) cells with rhLf showed the cell viability and morphology comparable to the control. In contrast, chemotherapeutic etoposide induced cytotoxicity in NHBE cells and reduced the cell viability by 40%. These results demonstrate the selective anticancer effects of rhLf against lung adenocarcinoma cells without cytotoxicity on normal human cells. This study highlights a potential for clinical utility of this novel rhLf in patients with lung cancer.

Citing Articles

Potential of Lactoferrin in the Treatment of Lung Diseases.

Kaczynska K, Jampolska M, Wojciechowski P, Sulejczak D, Andrzejewski K, Zajac D Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259341 PMC: 9960651. DOI: 10.3390/ph16020192.

Effects of Curcumin and Lactoferrin to Inhibit the Growth and Migration of Prostatic Cancer Cells.

Costantini E, Di Nicola M, Marchioni M, Aielli L, Reale M, Schips L Int J Environ Res Public Health. 2022; 19(23).

PMID: 36498267 PMC: 9737629. DOI: 10.3390/ijerph192316193.

Human Lactoferrin Synergizes with Etoposide to Inhibit Lung Adenocarcinoma Cell Growth While Attenuating Etoposide-Mediated Cytotoxicity of Human Endothelial Cells.

Olszewska P, Pazdrak B, Kruzel M Biomedicines. 2022; 10(10).

PMID: 36289691 PMC: 9598456. DOI: 10.3390/biomedicines10102429.

Lactoferrin as a Human Genome "Guardian"-An Overall Point of View.

Bukowska-Osko I, Sulejczak D, Kaczynska K, Kleczkowska P, Kramkowski K, Popiel M Int J Mol Sci. 2022; 23(9).

PMID: 35563638 PMC: 9105968. DOI: 10.3390/ijms23095248.

RIG-I Promotes Cell Viability, Colony Formation, and Glucose Metabolism and Inhibits Cell Apoptosis in Colorectal Cancer by NF-B Signaling Pathway.

Liu Y, Ye S, Zhu Y, Chen L, Zhang Z Dis Markers. 2022; 2022:1247007.

PMID: 35242239 PMC: 8888050. DOI: 10.1155/2022/1247007.

References

Cutone A, Rosa L, Ianiro G, Lepanto M, Bonaccorsi di Patti M, Valenti P . Lactoferrin's Anti-Cancer Properties: Safety, Selectivity, and Wide Range of Action. Biomolecules. 2020; 10(3). PMC: 7175311. DOI: 10.3390/biom10030456. View

Yang P, Wang J, Gong G, Sun X, Zhang R, Du Z . Cattle mammary bioreactor generated by a novel procedure of transgenic cloning for large-scale production of functional human lactoferrin. PLoS One. 2008; 3(10):e3453. PMC: 2565487. DOI: 10.1371/journal.pone.0003453. View

Ji Y, Qu Z, Zou X . Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway. Exp Toxicol Pathol. 2009; 63(1-2):69-78. DOI: 10.1016/j.etp.2009.09.010. View

Rodrigues L, Teixeira J, Schmitt F, Paulsson M, Lindmark Mansson H . Lactoferrin and cancer disease prevention. Crit Rev Food Sci Nutr. 2008; 49(3):203-17. DOI: 10.1080/10408390701856157. View

Kirkpatrick C, Green I, Rich R, SCHADE A . Inhibition of growth of Candida albicans by iron-unsaturated lactoferrin: relation to host-defense mechanisms in chronic mucocutaneous candidiasis. J Infect Dis. 1971; 124(6):539-44. DOI: 10.1093/infdis/124.6.539. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Jiang R, Lonnerdal B . Bovine lactoferrin and lactoferricin exert antitumor activities on human colorectal cancer cells (HT-29) by activating various signaling pathways. Biochem Cell Biol. 2017; 95(1):99-109. DOI: 10.1139/bcb-2016-0094. View

Guedes J, Pereira C, Rodrigues L, Corte-Real M . Bovine Milk Lactoferrin Selectively Kills Highly Metastatic Prostate Cancer PC-3 and Osteosarcoma MG-63 Cells . Front Oncol. 2018; 8:200. PMC: 5994723. DOI: 10.3389/fonc.2018.00200. View

Metz-Boutigue M, Jolles J, Mazurier J, Schoentgen F, Legrand D, SPIK G . Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur J Biochem. 1984; 145(3):659-76. DOI: 10.1111/j.1432-1033.1984.tb08607.x. View

10.

Almond R, Flanagan B, Antonopoulos A, Haslam S, Dell A, Kimber I . Differential immunogenicity and allergenicity of native and recombinant human lactoferrins: role of glycosylation. Eur J Immunol. 2012; 43(1):170-81. DOI: 10.1002/eji.201142345. View

11.

Okubo K, Kamiya M, Urano Y, Nishi H, Herter J, Mayadas T . Lactoferrin Suppresses Neutrophil Extracellular Traps Release in Inflammation. EBioMedicine. 2016; 10:204-15. PMC: 5006695. DOI: 10.1016/j.ebiom.2016.07.012. View

12.

Garcia-Montoya I, Cendon T, Arevalo-Gallegos S, Rascon-Cruz Q . Lactoferrin a multiple bioactive protein: an overview. Biochim Biophys Acta. 2011; 1820(3):226-36. PMC: 7127262. DOI: 10.1016/j.bbagen.2011.06.018. View

13.

Iglesias-Figueroa B, Siqueiros-Cendon T, Gutierrez D, Aguilera R, Espinoza-Sanchez E, Arevalo-Gallegos S . Recombinant human lactoferrin induces apoptosis, disruption of F-actin structure and cell cycle arrest with selective cytotoxicity on human triple negative breast cancer cells. Apoptosis. 2019; 24(7-8):562-577. PMC: 8935999. DOI: 10.1007/s10495-019-01539-7. View

14.

Remon J, Mezquita L, Corral J, Vilarino N, Reguart N . Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. J Thorac Dis. 2018; 10(Suppl 13):S1516-S1533. PMC: 5994490. DOI: 10.21037/jtd.2017.12.52. View

15.

Jiang R, Lonnerdal B . Apo- and holo-lactoferrin stimulate proliferation of mouse crypt cells but through different cellular signaling pathways. Int J Biochem Cell Biol. 2011; 44(1):91-100. DOI: 10.1016/j.biocel.2011.10.002. View

16.

Kruzel M, Actor J, Zimecki M, Wise J, Ploszaj P, Mirza S . Novel recombinant human lactoferrin: differential activation of oxidative stress related gene expression. J Biotechnol. 2013; 168(4):666-75. PMC: 3987904. DOI: 10.1016/j.jbiotec.2013.09.011. View

17.

Ward P, Piddington C, Cunningham G, Zhou X, Wyatt R, Conneely O . A system for production of commercial quantities of human lactoferrin: a broad spectrum natural antibiotic. Biotechnology (N Y). 1995; 13(5):498-503. DOI: 10.1038/nbt0595-498. View

18.

Kruzel M, Zimecki M, Actor J . Lactoferrin in a Context of Inflammation-Induced Pathology. Front Immunol. 2017; 8:1438. PMC: 5681489. DOI: 10.3389/fimmu.2017.01438. View

19.

Marth J, Grewal P . Mammalian glycosylation in immunity. Nat Rev Immunol. 2008; 8(11):874-87. PMC: 2768770. DOI: 10.1038/nri2417. View

20.

Ward P, Cunningham G, Conneely O . Commercial production of lactoferrin, a multifunctional iron-binding glycoprotein. Biotechnol Genet Eng Rev. 1997; 14:303-19. DOI: 10.1080/02648725.1997.10647946. View